Thrombocytosis on full blood count, previously uninvestigated, prompted hematological assessment and led to the diagnosis of a JAK2-positive myeloproliferative neoplasm, for which cytoreductive therapy was initiated alongside anticoagulation. Here, JAK2 is linked to thrombocytosis disease.